What is Tesamorelin?
Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) — the endogenous peptide that stimulates the pituitary gland to release growth hormone. As a 44-amino acid peptide modeled on the full native GHRH sequence, with a modification that extends its half-life, tesamorelin has been a key research tool for studying pulsatile GH release, IGF-1 production, and visceral fatty-acid metabolism.
What Tesamorelin Is
Tesamorelin is a synthetic analogue of GHRH, the hypothalamic peptide responsible for triggering pituitary growth hormone secretion. It mimics the full 44-amino acid sequence of human GHRH, with a structural modification that gives it greater resistance to enzymatic degradation and a longer half-life than native GHRH.
Because tesamorelin works upstream of growth hormone itself — at the level of the GHRH receptor on the pituitary — it stimulates the body's own GH-producing cells (somatotrophs) rather than introducing exogenous GH. This places it in a distinct research category from direct GH administration.
Mechanism of Action
Tesamorelin's research interest centers on its position in the GH/IGF-1 axis:
GHRH receptor binding: Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of endogenous growth hormone in its natural pulsatile pattern — rather than the sustained elevation seen with exogenous GH administration.
Pulsatile GH release: Because tesamorelin acts on the pituitary's own release machinery, the resulting GH secretion follows the body's normal pulsatile rhythm. This preserves the feedback regulation of the hypothalamic-pituitary GH axis, a key distinction researchers use when comparing GHRH analogues to direct GH or GH secretagogue approaches.
IGF-1 production: The increase in pulsatile GH release in turn increases hepatic production of IGF-1 (insulin-like growth factor 1), which mediates many of the downstream metabolic effects studied in tesamorelin research.
Research Applications
Tesamorelin is among the most clinically referenced GHRH analogues, with published research — including studies in JAMA — focused on the following areas:
| Research Area | Focus | Notes |
|---|---|---|
| Visceral adipose tissue | Visceral fat reduction | Primary focus of published JAMA research |
| Lean mass preservation | Body composition | Studied alongside fat-mass changes |
| Lipid metabolism | Triglycerides & lipid profile research | Downstream of IGF-1 / GH pathway activation |
| GH axis pharmacology | Pulsatile secretion studies | Used as a reference GHRH analogue |
The breadth of GH-axis-mediated effects makes tesamorelin a frequently referenced comparator compound in research on GHRH analogues and GH secretagogues more broadly.
Combination Research
Tesamorelin is sometimes studied alongside other research compounds to investigate cross-pathway effects:
With GLP-1 pathway compounds: Because tesamorelin's research focus (visceral fat, body composition via the GH/IGF-1 axis) and GLP-1/incretin pathway compounds (appetite, glucose metabolism) act through different mechanisms, researchers sometimes study the two together to characterize combined metabolic outcomes. In published research designs each compound is characterized separately in its own vial.
With other GH-axis compounds: As a GHRH receptor agonist, tesamorelin is mechanistically distinct from GH secretagogue stacks such as CJC-1295 + Ipamorelin (which combine a GHRH analogue with a ghrelin-receptor agonist). Comparative research between the two approaches can help isolate the contribution of each receptor pathway. For more on the CJC-1295 + Ipamorelin mechanism, see our What is CJC-1295? guide.
With mitochondrial/AMPK compounds: Tesamorelin's GH/IGF-1 axis activity is mechanistically distinct from MOTS-C, a mitochondria-derived peptide that activates AMPK directly at the cellular level. Comparative research between the two can help separate hormone-axis-mediated effects from direct cellular energy-sensing effects. See our Tesamorelin vs MOTS-C comparison for a full breakdown.
Preparation for Research
Tesamorelin is supplied as a lyophilized (freeze-dried) powder and is dissolved in Bacteriostatic Water before use in research protocols.
Storage: Store the lyophilized (freeze-dried) powder refrigerated at 2–8°C — or at room temperature for short periods — protected from light and moisture. Once in solution, keep it refrigerated at 2–8°C and do not freeze; peptides in solution typically remain stable for roughly 28–42 days.